{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:55:44Z","timestamp":1793055344584,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Thrombotic events are one of the main factors affecting the survival of patients with Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs). Therefore, a comprehensive understanding of the early relevant high-risk factors makes sense for early prevention and reducing mortality in these patients. In this study, we conducted a retrospective analysis of 336 patients with Ph- MPN and summarized the clinical characteristics, incidence of thrombotic events and influencing factors. Thrombotic events occurred in 27.7% (93\/336) of patients. Among the thrombotic events, arterial thrombosis occurred in 86 cases (92.5%), the most common thrombotic event was cerebral infarction (69\/93, 74.2%). Univariate analysis and logistic regression identified that diagnosis of Polycythemia Vera (PV)\/Essential Thrombocythemia (ET), thrombotic events before diagnosis and D-dimer\u22651mg\/L were the independent risk factors for thrombotic events at initial diagnosis in MPN patients (<jats:italic>P<\/jats:italic>&amp;lt;0.05). Receiver operating characteristic (ROC) curve analysis revealed that the integrated predictive efficacy of the triple-variable combination was markedly superior to that of any single parameter alone, yielding a sensitivity of 72.04% (95% CI: 61.8%-80.9%), a specificity of 74.49% (95% CI: 68.5%-79.8%), and an area under the curve (AUC) of 0.771 (95% CI: 0.723 - 0.815). Additionally, univariate analysis further identified smoking history, elevated hemoglobin (Hb\u2265136g\/L), hematocrit (HCT\u22650.42), D-dimer-to-fibrinogen ratio (DFR\u22650.243) and JAK2<jats:sup>V617F<\/jats:sup> mutation as potential risk factors for thrombosis (<jats:italic>P<\/jats:italic>&amp;lt;0.05), necessitating validation in future studies. These findings facilitate the early identification of Ph-MPN patients at heightened risk for thrombotic events, enabling the implementation of targeted prophylactic strategies to mitigate thrombotic risk.<\/jats:p>","DOI":"10.3389\/fonc.2025.1639250","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:11:15Z","timestamp":1756786275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors for thrombotic events in Philadelphia chromosome-negative myeloproliferative neoplasms: a retrospective analysis of 336 cases"],"prefix":"10.3389","volume":"15","author":[{"given":"Lingxiu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmei","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41408-024-01169-6","article-title":"Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors","volume":"14","author":"Barbui","year":"2024","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13373","article-title":"Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up","volume":"104","author":"Ahlstrand","year":"2020","journal-title":"Eur J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2021_210729N1068","article-title":"Risk factors of thrombosis in a cohort of 206 patients with BCR-ABL1 negative myeloproliferative neoplasms","volume":"68","author":"Aswad","year":"2021","journal-title":"Neoplasma"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The\u00a02016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41408-023-00887-7","article-title":"Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach","volume":"13","author":"Carobbio","year":"2023","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41408-023-00960-1","article-title":"The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients","volume":"13","author":"Barbui","year":"2023","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1757230","article-title":"Correlation of thrombosis and clinicohematological parameters with JAK2V617F mutation in philadelphia-negative CMPNs: A study from India","volume":"14","author":"Singh K","year":"2022","journal-title":"J Lab Physicians"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-024-03776-5","article-title":"Association between JAK2(V617F) variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms","volume":"193","author":"Brown","year":"2024","journal-title":"Ir J Med Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221097969","article-title":"Thrombotic and hemorrhagic issues associated with myeloproliferative neoplasms","volume":"28","author":"Papageorgiou","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/ijms25031417","article-title":"Red blood cell contribution to thrombosis in polycythemia vera and essential thrombocythemia","volume":"25","author":"Grenier","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/ejh.13516","article-title":"Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia","volume":"106","author":"Buxhofer-Ausch","year":"2021","journal-title":"Eur J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2621-2","article-title":"Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)","volume":"95","author":"Appelmann","year":"2016","journal-title":"Ann Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1003-6350.2023.21.010","article-title":"Value of thromboelastography in evaluating the coagulation status of patients with Philadelphia chromosome-negative myeloproliferative neoplasm","volume":"21","author":"Zhang","year":"2023","journal-title":"Oncol Prog"},{"key":"B24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1515\/hmbci-2022-0093","article-title":"D-dimer-a multifaceted molecule","volume":"45","author":"Tayal","year":"2024","journal-title":"Horm Mol Biol Clin Investig"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2020-210688","article-title":"Could a D-dimer\/fibrinogen ratio have a role in ruling-out venous thromboembolism","volume":"39","author":"Marcian\u00f2","year":"2022","journal-title":"Emerg Med J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-024-00664-x","article-title":"A retrospective cohort study on a novel marker to predict the severity and prognosis of acute cerebral venous thrombosis: D-dimer to fibrinogen ratio","volume":"22","author":"Lan","year":"2024","journal-title":"Thromb J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.11877\/j.issn.1672-1535.2023.21.24.21","article-title":"Related factors of thrombosis in patients with chronic myeloproliferative neoplasms and the predictive efficacy of peripheral blood RPR and DFR for thrombosis","volume":"34","author":"Guo","year":"2023","journal-title":"Hai Nan Med J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02681-9","article-title":"QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms","author":"Duminuco","year":"2025","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1639250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:11:18Z","timestamp":1756786278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1639250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1639250"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1639250","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1639250"}}